Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
Purpose. The aim was to evaluate the efficacy of aflibercept in patients with diabetic macular edema (DME) unresponsive to prior anti-VEGF therapy. Methods. Retrospective review of DME unresponsive to previous anti-VEGF switched to aflibercept with 3 months of follow-up. Changes in best correct visu...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2017/5632634 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567661422182400 |
|---|---|
| author | Filipe Mira Manuel Paulo Filipe Henriques João Figueira |
| author_facet | Filipe Mira Manuel Paulo Filipe Henriques João Figueira |
| author_sort | Filipe Mira |
| collection | DOAJ |
| description | Purpose. The aim was to evaluate the efficacy of aflibercept in patients with diabetic macular edema (DME) unresponsive to prior anti-VEGF therapy. Methods. Retrospective review of DME unresponsive to previous anti-VEGF switched to aflibercept with 3 months of follow-up. Changes in best correct visual acuity (BCVA), central retinal thickness (CRT), and frequency of injections were analyzed. The percentage of subjects who had ≥20/40 (logMAR equivalent 0.3) and ≤20/200 (logMAR equivalent 1) was evaluated. Results. A total of 32 eyes from 26 patients were included. Mean age was 65 ± 10 years old. The mean number of previous anti-VEGF injections was 5.34 ± 2.38, and the mean number of aflibercept injections at the end of the study was 2.00 ± 0.00. The CRT at baseline was 501.47 ± 150.51 μm and 367.97 ± 124.61 μm at 3 months of follow-up (P<0.001). The logMAR BCVA at baseline was 0.71 ± 0.36 and 0.65 ± 0.33 at the end of the follow-up (P=0.037). At baseline, 12.5% of patients had ≥20/40 compared with 25% at the end of follow-up. At baseline, 28.13% of patients had 20/200 or inferior vision compared with 15.63% at the end of the follow-up. Conclusions. DME patients unresponsive to previous multiple ranibizumab injections demonstrate a significant anatomical and functional improvement with the switch to aflibercept. |
| format | Article |
| id | doaj-art-90bf6468148f4c389c32f8b282313039 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-90bf6468148f4c389c32f8b2823130392025-02-03T01:00:51ZengWileyJournal of Ophthalmology2090-004X2090-00582017-01-01201710.1155/2017/56326345632634Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF TherapyFilipe Mira0Manuel Paulo1Filipe Henriques2João Figueira3Centro Hospitalar Médio Tejo, Tomar, PortugalCentro Hospitalar Médio Tejo, Tomar, PortugalCentro Hospitalar e Universitário de Coimbra, Coimbra, PortugalCentro Hospitalar e Universitário de Coimbra, Coimbra, PortugalPurpose. The aim was to evaluate the efficacy of aflibercept in patients with diabetic macular edema (DME) unresponsive to prior anti-VEGF therapy. Methods. Retrospective review of DME unresponsive to previous anti-VEGF switched to aflibercept with 3 months of follow-up. Changes in best correct visual acuity (BCVA), central retinal thickness (CRT), and frequency of injections were analyzed. The percentage of subjects who had ≥20/40 (logMAR equivalent 0.3) and ≤20/200 (logMAR equivalent 1) was evaluated. Results. A total of 32 eyes from 26 patients were included. Mean age was 65 ± 10 years old. The mean number of previous anti-VEGF injections was 5.34 ± 2.38, and the mean number of aflibercept injections at the end of the study was 2.00 ± 0.00. The CRT at baseline was 501.47 ± 150.51 μm and 367.97 ± 124.61 μm at 3 months of follow-up (P<0.001). The logMAR BCVA at baseline was 0.71 ± 0.36 and 0.65 ± 0.33 at the end of the follow-up (P=0.037). At baseline, 12.5% of patients had ≥20/40 compared with 25% at the end of follow-up. At baseline, 28.13% of patients had 20/200 or inferior vision compared with 15.63% at the end of the follow-up. Conclusions. DME patients unresponsive to previous multiple ranibizumab injections demonstrate a significant anatomical and functional improvement with the switch to aflibercept.http://dx.doi.org/10.1155/2017/5632634 |
| spellingShingle | Filipe Mira Manuel Paulo Filipe Henriques João Figueira Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy Journal of Ophthalmology |
| title | Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy |
| title_full | Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy |
| title_fullStr | Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy |
| title_full_unstemmed | Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy |
| title_short | Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy |
| title_sort | switch to aflibercept in diabetic macular edema patients unresponsive to previous anti vegf therapy |
| url | http://dx.doi.org/10.1155/2017/5632634 |
| work_keys_str_mv | AT filipemira switchtoafliberceptindiabeticmacularedemapatientsunresponsivetopreviousantivegftherapy AT manuelpaulo switchtoafliberceptindiabeticmacularedemapatientsunresponsivetopreviousantivegftherapy AT filipehenriques switchtoafliberceptindiabeticmacularedemapatientsunresponsivetopreviousantivegftherapy AT joaofigueira switchtoafliberceptindiabeticmacularedemapatientsunresponsivetopreviousantivegftherapy |